Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19]

The authors regret that panel E of Fig. 1 was missing, showing the cumulative incidence of the primary outcome in hematologic cancer.

Source: Thrombosis Research - March 5, 2020 Category: Hematology Authors: F.I. Mulder, N. van Es, N. Kraaijpoel, M. Di Nisio, M. Carrier, A. Duggal, M. Gaddh, D. Garcia, M.A. Grosso, A.K. Kakkar, M.F. Mercuri, S. Middeldorp, G. Royle, A. Segers, S. Shivakumar, P. Verhamme, T. Wang, J.I. Weitz, G. Zhang, H.R. B üller, G. Raskob Source Type: research